Hot News
Personalized mRNA Vaccine Plus Pembrolizumab Shows Durable 5-Year Benefit in High-Risk Melanoma
New long-term findings presented at the 2026 ASCO Annual Meeting suggest that personalized mRNA cancer vaccines may become a promising future direction in oncology